Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Assembly Biosciences (ASMB) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Assembly Biosciences (ASMB) over the last 8 years, with Q3 2025 value amounting to 83.48%.

  • Assembly Biosciences' EBITDA Margin rose 549500.0% to 83.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 103.47%, marking a year-over-year increase of 401600.0%. This contributed to the annual value of 141.33% for FY2024, which is 7033700.0% up from last year.
  • Assembly Biosciences' EBITDA Margin amounted to 83.48% in Q3 2025, which was up 549500.0% from 106.21% recorded in Q2 2025.
  • Assembly Biosciences' EBITDA Margin's 5-year high stood at 83.48% during Q3 2025, with a 5-year trough of 300.9% in Q3 2021.
  • Its 4-year average for EBITDA Margin is 145.07%, with a median of 138.44% in 2024.
  • As far as peak fluctuations go, Assembly Biosciences' EBITDA Margin tumbled by -2904600bps in 2021, and later surged by 655700bps in 2025.
  • Assembly Biosciences' EBITDA Margin (Quarter) stood at 300.9% in 2021, then skyrocketed by 50bps to 150.33% in 2023, then grew by 6bps to 141.23% in 2024, then surged by 41bps to 83.48% in 2025.
  • Its EBITDA Margin stands at 83.48% for Q3 2025, versus 106.21% for Q2 2025 and 94.07% for Q1 2025.